Table II.
Summary of features at recurrence, N=60
| Feature | N (%) |
|---|---|
| Age at recurrence | |
| Pediatric | 14 (23) |
| Adult | 46 (77) |
| Sex | |
| Women | 33 (55) |
| Men | 27 (45) |
| Race/ethnicity | |
| White | 52 (87) |
| Asian/Pacific Islander | 7 (12) |
| Other | 1 (2) |
| Visit setting | |
| Emergency department | 52 (87) |
| Clinic | 1 (2) |
| Allergy clinic | 5 (8) |
| Other | 2 (3) |
| Disposition | |
| Home | 45 (75) |
| Observation unit | 4 (7) |
| Hospital ward | 4 (7) |
| Intensive care unit | 7 (12) |
| Inciting allergen | |
| Food | 20 (33) |
| Medication | 5 (8) |
| Contrast | 1 (2) |
| Venom | 7 (12) |
| Unknown | 17 (28) |
| Other | 10 (17) |
| Allergist saw patient after index anaphylaxis | 25 (42) |
| Inciting allergen identified by allergist (N=25) | 15 (60) |
| Allergy tests performed | 12 (20) |
| Mucocutaneous symptom | 57 (95) |
| Gastrointestinal tract symptom | 12 (20) |
| Cardiovascular symptom | 30 (50) |
| Respiratory tract symptom | 39 (65) |
| Steroid provided as therapy | 45 (75) |
| Epinephrine provided as therapy | 39 (65) |
| Location of first epinephrine (N=39) | |
| Self/home | 16 (41) |
| EMS/resuscitation team | 3 (8) |
| Emergency department | 18 (46) |
| Other | 2 (5) |
| Access to epinephrine autoinjector | 44 (73) |